Home › Prediabetes › NCT06424106
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
Who can join
Ages 25 to 65 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance Exclusion Criteria: * HbA1c less than 6.5% * Use of any glucose-lowering agents including metformin or sulfonylureas. * For female subjects: positive pregnancy test at the time of enrollment or study * History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. * Active systemic illness or malignancy. * Symptomatic macrovascular or microvascular disease.
About the study
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
What is being tested
- Glucagon (other)
- Glucose (other)
Sponsor: Mayo Clinic · Participants: 60 · Started: Apr 1, 2025
Contact the study team
- Kim Osmundson, CCRP · Phone: 507-255-0907
- Jeanette Laugen · Phone: 507-255-8110
Official record on ClinicalTrials.gov — NCT06424106
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.